Stiris Research Inc. Awarded Phase I Metastatic Resistant Prostate Cancer Trial with Bone Metastasis Trial

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces the award of a Phase Metastatic Resistant Prostate Cancer (MRPC) with Bone Metastasis study.

“We are thrilled to be working on this study, in hopes to find new ways to help prostate cancer participants with bone metastasis. We have worked with this Sponsor for many years and are excited to continue our collaboration with them on the potential new direction for their investigational product.  It has been a true collaborative process, involving the Sponsor, CRO team, and Investigational site, allowing us to reach regulatory approval stage much faster than we have typically seen,” said Carrie Hamilton, Senior Director of Clinical Science.

MRPC occurs when prostate cancer evolves to resist standard treatment with androgen deprivation therapy (ADT), which blocks the production and signaling activity of hormones called androgens (such as testosterone) that fuel the cancer’s growth. Most CRPCs are diagnosed as metastatic (mCRPC), meaning they have already spread beyond the prostate; only about 16% are caught prior to metastasis (non-metastatic CRPC, or nmCRPC).  (https://cancercommons.org/latest-insights/new-treatments-castrate-resistant-prostate-cancer/)

Bone metastasis occurs when cancer cells spread from their original site to a bone. Nearly all types of cancer can spread (metastasize) to the bones. But some types of cancer are particularly likely to spread to bone, including breast cancer and prostate cancer. (https://www.mayoclinic.org/diseases-conditions/bone-metastasis/symptoms-causes/syc-20370191#:~:text=Bone%20metastasis%20occurs%20when%20cancer,breast%20cancer%20and%20prostate%20cancer.)